

Clinical trials of Reviparin

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
Reviparin vs placebo			
CREATE , 2005 n=7780/7790 follow-up: 30 d	Reviparin 34366871 IU BID for 7 d (weight adjusted) versus placebo	patients with acute myocardial infarction, STEMI or new LBBB, <=12 h	Parallel groups Double-blind

More details and results :

- antithrombotics for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q36>

References

CREATE, 2005:

Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, Zhu J, Liu L Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293:427-35 [[15671427](#)]

2 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
reviparin vs control			
Wirth , 2001 n=117/122 follow-up: 7-10 days	reviparin 1,750 anti Xa IU Sc once daily for 7-10 days versus no treatment	elective knee arthroscopy	Parallel groups open (blind assesment) Germany
reviparin vs placebo			
Lassen , 2002 n=183/188 follow-up: 43 days	Reviparin 1750 IU versus Placebo	patients who required immobilization in a plaster cast or brace for at least five weeks after a leg fracture or rupture of the Achilles tendon	Parallel groups double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
reviparin vs unfractionated heparin			
Kakkar , 1993 n=672/679	Reviparin 1750 anti Xa units versus UFH 10 000 units	General and gynaecological surgery	Blind

More details and results :

- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antithrombotics for thrombosis prevention in arthroscopy at <http://www.trialresultscenter.org/go-Q150>
- heparin (UFH or LMWH) for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q195>
- LMWH for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q196>
- antithrombotics for thrombosis prevention in patients with immobilization of the lower extremities at <http://www.trialresultscenter.org/go-Q405>

References

Wirth, 2001:

Wirth T, Schneider B, Misselwitz F, Lomb M, Tyl H, Egbring R, Griss P Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. *Arthroscopy* 2001;17:393-9 [[11288011](#)]

Lassen, 2002:

Lassen MR, Borris LC, Nakov RL Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. *N Engl J Med* 2002;347:726-30 [[12213943](#)] [10.1056/NEJMoa011327](#)

Kakkar, 1993:

3 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
reviparin vs UFH			
REDUCE , 1996 n=306/306 follow-up: 3 days	65279;Reviparin 7,000 IU anti-Xa versus UFH 10,000 IU bolus	PTCA with stable/unstable angina	Parallel groups double blind Europe and Canada

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- anticoagulant for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q388>

References

REDUCE, 1996:

Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996;28:1437-43 [[8917255](#)]

4 pulmonary embolism

Trial	Treatments	Patients	Trials design and methods
Reviparin vs unfractionated heparin			
COLOMBUS sub group , 1997 n=138/133 follow-up: 3 mo	Reviparin, 35006300 IU twice daily, 5 days versus Unfractionated heparin: bolus 5000 IU, infusion 1250 IU/h	patients with symptomatic DVT and associated pulmonary embolism	Parallel groups open

More details and results :

- antithrombotics for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q102>

References

COLOMBUS sub group, 1997:

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997;337:657-62 [[9280815](#)]

Entry terms: reviparin, reviparin, reviparine, reviparin-sodium, reviparin sodium, LU 47311, LU-47311, Clivarin, Abbott brand of reviparin-sodium, Clivarine, ICN brand of reviparin-sodium,